Wet AMD (Age-Related Macular Degeneration)
Wet age-related macular degeneration is a leading cause of vision loss in people over 50. It occurs when abnormal blood vessels grow beneath the retina and leak fluid or blood, causing rapid damage to the macula — the part of the eye responsible for central vision. Without treatment, wet AMD can cause permanent, irreversible vision loss within weeks to months.
You may qualify for clinical trials that provide Eylea at no cost
Clinical trials may give you access to this treatment while helping advance medical research
Search TrialsMany commercial insurers require trial of off-label bevacizumab (Avastin, ~$50/injection) before approving branded anti-VEGF agents (Eylea ~$1,850, Lucentis ~$1,170 per injection). Medicare Part B typically does not impose step therapy for anti-VEGF agents. Vabysmo (faricimab) offers extended dosing intervals but may require failure of other agents first.
Preferred anti-VEGF agent required (Avastin before Eylea or Lucentis)
Very Common
Frequency of injections exceeds payer limits
Common
OCT imaging not submitted showing active disease
Common
Vabysmo denied without trial of other anti-VEGF agents first
Occasional
Bilateral treatment denied or limited to one eye at a time
Occasional
- 1.Submit OCT imaging showing subretinal or intraretinal fluid, or choroidal neovascularization
- 2.Document visual acuity (Snellen chart) and visual acuity change over time
- 3.If Avastin failed or is inappropriate, document specific reasons (e.g., inadequate response, silicone oil contamination risk)
- 4.For Vabysmo requests, document frequency of current injections and potential benefit of extended intervals
- 5.Cite AAO Preferred Practice Pattern guidelines supporting anti-VEGF therapy as standard of care
Active clinical trials that may provide treatment at no cost.
Copay cards, patient assistance programs, and foundation grants for this condition's treatments.
Want to know what you'll actually pay?
Estimate your annual out-of-pocket cost with and without assistance programs.
Estimate My CostsDenied for Wet AMD (Age-Related Macular Degeneration) Treatment?
Ellen can decode your denial, find your appeal strategy, and generate your appeal letter — free.